(Q31974227)

5 July 2017

1 reference

title

New uses of older antibiotics (English)

1 reference

5 July 2017

0 references

Klein NC

1

1 reference

5 July 2017

Cunha BA

series ordinal

2

1 reference

5 July 2017

publication date

1 January 2001

1 reference

Medical Clinics of North America

5 July 2017

published in

1 reference

5 July 2017

volume

85

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

125-132

1 reference

Antimicrobial susceptibility of coagulase-negative staphylococci

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Metabolism of chloramphenicol: a story of nearly 50 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

Doxycycline re-revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Antimicrobial treatment of Helicobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Clindamycin, metronidazole, and chloramphenicol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Parenteral therapy for antibiotic-associated pseudomembranous colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Vancomycin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Methicillin-resistant Staphylococcus aureus as a community organism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Metronidazole treatment in rosacea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Doxycycline activity against Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Trimethoprim-sulfamethoxazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Trimethoprim-sulfamethoxazole in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

Diagnosis and management of HIV-associated periodontal lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Minocycline as an alternative antistaphylococcal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970307-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70307-2

1 reference

5 July 2017

1 reference